HAIFA, Israel and MIAMI, Nov. 2, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that the editorial panel of the American Medical Association (AMA) approved their application to establish a new Category (Cat) I Current Procedural Terminology (CPT®) code to facilitate reimbursement for MR-guided focused ultrasound (MRgFUS) ablation of neurological targets. The Cat I CPT® code will be included in the next CPT® codebook and expected to be effective January 1, 2025.
Insightec Announces Milestone of First Patients Enrolled in the Pivotal LIBERATE Clinical Trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors)
HAIFA, Israel and MIAMI, Sep. 1, 2022 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund. The financing has provided Insightec with $100 million at closing, with an additional $100 million of financing potentially available in tranches through 2024. The credit facility is interest-only for five years and matures on August 31, 2027.
While Insightec has raked in hundreds of millions of dollars in VC funding in recent years based largely on the strength of its Exablate Neuro platform, the company continues to expand its focused ultrasound technology beyond the brain.
HAIFA, Israel and MIAMI, Fla., Dec. 1, 2021 /PRNewswire/ -- Insightec, a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy, announced today that the Exablate Prostate system received FDA 510K clearance for treating prostate tissue with high intensity Focused Ultrasound.